dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Calvi, Alberto |
dc.contributor.author | Mendelsohn, Zoe |
dc.contributor.author | Hamed, Weaam |
dc.contributor.author | Chard, Declan |
dc.contributor.author | Stutters, Jonathan |
dc.contributor.author | TUR, CARMEN |
dc.date.accessioned | 2024-02-02T09:49:28Z |
dc.date.available | 2024-02-02T09:49:28Z |
dc.date.issued | 2024-01 |
dc.identifier.citation | Calvi A, Mendelsohn Z, Hamed W, Chard D, Tur C, Stutters J, et al. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis. Eur J Neurol. 2024 Jan;31(1):e16092. |
dc.identifier.issn | 1351-5101 |
dc.identifier.uri | https://hdl.handle.net/11351/10962 |
dc.description | Lesions actives cròniques; Esclerosi múltiple primària progressiva; Ressonància magnètica volumètrica |
dc.description.sponsorship | A. Calvi is supported by the ECTRIMS post-doctoral training fellowship (2022), previously received a UK MS Society PhD studentship (2020), a Guarantors of Brain “Entry” clinical fellowship (2019), and an ECTRIMS-MAGNIMS fellowship (2018). He has received travel support from the UK MS society, ECTRIMS and NAIMS. Z. Mendelsohn and B. Kanber are supported by the National Institute for Health and Research (NIHR) Biomedical Research Centre (BRC) initiative at University College London Hospitals (UCLH). W. Hamed, J Stutters have nothing to disclose in relation to this study. D. Chard is a consultant for Hoffmann-La Roche. In the last three years he has been a consultant for Biogen, has received research funding from Hoffmann-La Roche, the International Progressive MS Alliance, the MS Society, the Medical Research Council, and the NIHR UCLH Biomedical Research Centre, and a speaker's honorarium from Novartis. He co-supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck. C. Tur has received 2021 Merck's Award for the Investigation in Multiple Sclerosis, Junior Leader La Caixa Fellowship in 2020, ECTRIMS Post-doctoral Research Fellowship in 2015; honoraria and support for travelling from Merck Serono, Sanofi, Roche, TEVA Pharmaceuticals, Novartis, Biogen, Bayer, Ismar Healthcare. F. Barkhof is supported by the NIHR BRC initiative at UCLH, and he serves on the steering committee, or he is iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. C. Gandini Wheeler-Kingshott has received funding from the MS Society (#77), Wings for Life (#169111), Horizon2020 (Human Brain Project SGA3, Specific Grant Agreement No. 945539), BRC (#BRC704/CAP/CGW), MRC (#MR/S026088/1), Ataxia UK. F. Prados received a Guarantors of Brain fellowship 2017-2020 and is supported by NIHR BRC initiative at UCLH. F. Barkhof, D. Mac Manus and C. Gandini Wheeler-Kingshott declare competing interests as share-holders in Queen Square Analytics LTD. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | European Journal of Neurology;31(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Imatgeria per ressonància magnètica |
dc.subject | Medicaments immunosupressors |
dc.subject.mesh | Immunosuppressive Agents |
dc.subject.mesh | Magnetic Resonance Imaging |
dc.subject.mesh | Multiple Sclerosis, Chronic Progressive |
dc.title | Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/ene.16092 |
dc.subject.decs | inmunosupresores |
dc.subject.decs | imagen por resonancia magnética |
dc.subject.decs | esclerosis múltiple crónica progresiva |
dc.relation.publishversion | https://doi.org/10.1111/ene.16092 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Calvi A] NMR Research Unit, Institute of Neurology, University College London, London, UK. Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Fundació Clinic per a la Recerca Biomèdica, Barcelona, Spain. [Mendelsohn Z] NMR Research Unit, Institute of Neurology, University College London, London, UK. Department of Radiology, Charité School of Medicine and University Hospital Berlin, Berlin, Germany. [Hamed W] NMR Research Unit, Institute of Neurology, University College London, London, UK. Department of Radiology, Mansoura University Hospital, Mansoura, Egypt. [Chard D] NMR Research Unit, Institute of Neurology, University College London, London, UK. National Institute for Health Research, Biomedical Research Centre, University College London Hospitals, London, UK. [Tur C] NMR Research Unit, Institute of Neurology, University College London, London, UK. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. [Stutters J] NMR Research Unit, Institute of Neurology, University College London, London, UK |
dc.identifier.pmid | 37823722 |
dc.identifier.wos | 001084206400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |